Raie T Bekele
Overview
Explore the profile of Raie T Bekele including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
P Shanmugam S, Zhou Y, Stelter I, Hanlon T, Bekele R, Bellmunt J, et al.
Bladder Cancer
. 2025 Mar;
11(1):23523735251317865.
PMID: 40034244
Background: Enfortumab vedotin (EV) and Sacituzumab govitecan (SG) are antibody-drug conjugates (ADCs) with demonstrated activity in advanced bladder cancer. A subset of bladder tumors harbors a DNA repair deficiency in...
2.
Zhou Y, DAndrea V, P Shanmugam S, Stelter I, Stormoen D, Chroneos R, et al.
Eur Urol
. 2024 Mar;
86(1):69-71.
PMID: 38523005
No abstract available.
3.
Zhou Y, Borcsok J, Adib E, Kamran S, Neil A, Stawiski K, et al.
Sci Adv
. 2023 Nov;
9(47):eadg2263.
PMID: 37992168
Ataxia-telangiectasia mutated (ATM) plays a central role in the cellular response to DNA damage and ATM alterations are common in several tumor types including bladder cancer. However, the specific impact...
4.
Dillon K, Bekele R, Sztupinszki Z, Hanlon T, Rafiei S, Szallasi Z, et al.
NPJ Precis Oncol
. 2022 Jun;
6(1):49.
PMID: 35768576
PARP inhibitors were recently approved for treatment of molecularly-defined subsets of metastatic castrate-resistant prostate cancer (mCRPC) patients. Although the PARP inhibitor olaparib was approved for use in patients with a...
5.
Bekele R, Samant A, Nassar A, So J, Garcia E, Curran C, et al.
J Clin Invest
. 2021 Sep;
131(22).
PMID: 34554931
Bladder cancer is a genetically heterogeneous disease, and novel therapeutic strategies are needed to expand treatment options and improve clinical outcomes. Here, we identified a unique subset of urothelial tumors...
6.
Benesch M, Tang X, Venkatraman G, Bekele R, Brindley D
J Biomed Res
. 2016 Aug;
30(4):272-84.
PMID: 27533936
Extracellular lysophosphatidate (LPA) is a potent bioactive lipid that signals through six G-protein-coupled receptors. This signaling is required for embryogenesis, tissue repair and remodeling processes. LPA is produced from circulating...
7.
Bekele R, Venkatraman G, Liu R, Tang X, Mi S, Benesch M, et al.
Sci Rep
. 2016 Feb;
6:21164.
PMID: 26883574
Tamoxifen is the accepted therapy for patients with estrogen receptor-α (ERα)-positive breast cancer. However, clinical resistance to tamoxifen, as demonstrated by recurrence or progression on therapy, is frequent and precedes...
8.
Samadi N, Bekele R, Goping I, Schang L, Brindley D
PLoS One
. 2011 Jun;
6(5):e20608.
PMID: 21647386
Background: Taxol is a microtubule stabilizing agent that arrests cells in mitosis leading to cell death. Taxol is widely used to treat breast cancer, but resistance occurs in 25-69% of...